Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00364247
Other study ID # CR011215
Secondary ID
Status Completed
Phase Phase 3
First received August 11, 2006
Last updated June 2, 2011
Est. completion date May 2007

Study information

Verified date June 2011
Source Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness (level of pain control) and safety of the administration of 3 different dose levels of CG5503 compared with oxycodone and with placebo in patients who have had a bunionectomy, and to assess the safety of the drug for 9 days after patients are discharged from the hospital.


Description:

Patients undergoing bunionectomy often experience moderate to severe acute pain post-surgery. Normally such pain is controlled when patients receive repeated doses of opioid analgesics. However, opioid therapy is commonly associated with side effects such as nausea, vomiting, sedation, constipation, addiction, tolerance, and respiratory depression. CG5503, a newly synthesized drug also acts as a centrally acting analgesic but has a dual mode of action. The aim of this study is to investigate the effectiveness (level of pain control) and safety (side effects) of 3 dose levels of CG5503 Immediate Release (IR) compared to no drug (placebo) or one dose level of oxycodone (an opioid commonly used to treat post-surgical pain). This study is a randomized (patients are assigned different treatments based on chance), double-blind (neither investigator nor patient will know which treatment is received), active- and placebo-controlled, parallel-group, multicenter study to evaluate treatment of the acute pain from bunionectomy. The study will include a blinded 72 hour inpatient phase immediately following bunionectomy, during which patients will be treated with either 50-, 75-, or 100-mg CG5503 IR base, a placebo, or 15-mg oxycodone IR, and pain intensity and pain relief will be periodically assessed. Following this phase, patients wishing to continue treatment with CG5503 IR may enter an outpatient voluntary nonrandomized, open-label extension phase for 9 days when they will receive 50- or 100-mg CG5503 IR. Assessments of pain relief include the pain intensity numeric rating scale (PI), pain relief numeric rating scale (PAR), and patient global impression of change scale (PGIC). Safety evaluations include monitoring of adverse events, physical examinations, and clinical laboratory tests. Venous blood samples will be collected for the determination of serum concentrations of CG5503 and oxycodone. The null hypothesis for the study is that efficacy results for all CG5503 IR dosage groups are equal to placebo based on the mean sum of pain intensity difference at 48 hours. The alternative study hypothesis is that at least 1 dose strength of CG5503 will be different from placebo in controlling pain at 48 hours. CG5503 IR 50, or 75, or 100 mg (of the base), or oxycodone 15 mg, or placebo: 1 capsule taken every 4 to 6 hours during the 72-hour postsurgery phase of the study; and CG5503, 50 mg capsules, 1 to 2 tablets taken by mouth every 4 to 6 hours for up to 9 days during the open label portion of the study. All doses of study treatment will be taken with approximately 120 mL of water with or without food.


Recruitment information / eligibility

Status Completed
Enrollment 602
Est. completion date May 2007
Est. primary completion date May 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Patients must undergo primary unilateral first metatarsal bunionectomy

- pain intensity must be moderate to severe following stoppage of a continuous popliteal sciatic block (a nerve block with local anesthetic that numbs the foot)

- female patients must be postmenopausal, surgically sterile, or practicing an effective method of birth control if they are sexually active.

Exclusion Criteria:

- Patients will be excluded from the study if they have a history of seizure disorder or epilepsy

- history of malignancy within the past 2 years before starting the study

- history of alcohol or drug abuse

- evidence of active infections that may spread to other areas of the body

- clinical laboratory values reflecting moderate or severe renal insufficiency

- currently treated with anticonvulsants, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), neuroleptics, or serotonin norepinephrine reuptake inhibitor (SNRI).

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Intervention

Drug:
CG5503 IR;tapentadol


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Grünenthal GmbH

Outcome

Type Measure Description Time frame Safety issue
Primary The primary effectiveness outcome for this study is SPID48 (i.e., the sum of pain intensity difference at 48 hours relative to the first dose).
Secondary Secondary effectiveness outcomes include, among others, the effect of CG5503 IR on the time to the need for the first rescue pain medication during the double-blind treatment period, and the SPID at 12, 24, and 72 hours relative to first dose.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04473196 - The Effect of Weight Bearing on Patient Outcomes Following 1st MTP Joint Fusion N/A
Recruiting NCT05587569 - Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D) N/A
Recruiting NCT05555459 - Performance and Safety Evaluation of Inion CompressOn Screw in Foot and Ankle Surgeries. PMCF Investigation N/A
Completed NCT02121119 - Lidocaine Versus Bupivacaine in Ambulatory Continuous Block With Elastomeric Pump Phase 4
Enrolling by invitation NCT00600899 - Home Infusors for Analgesia After Foot Surgery Phase 4
Completed NCT05579054 - Translation, Validity, and Reliability of the Foot Posture Index (FPI-6) - Turkish Version
Terminated NCT05082012 - Early Weight-Bearing After the Lapiplasty Mini-Incision Procedure (Mini3D) N/A
Recruiting NCT05051709 - Can Hypermobility of First Ray Affect Surgical Treatment of Hallux Valgus N/A
Recruiting NCT04716140 - Prospective Study: The Effect on Clinical Outcome After Treatment of MTP Cartilage Lesions in Hallux Valgus Surgery N/A
Active, not recruiting NCT04145882 - Efficacy of Additional Osteotomies to Correct Hallux Valgus N/A
Completed NCT04468555 - Hallux Valgus Manual Therapy Based on Global Postural Reeducation. N/A
Terminated NCT03257540 - Early Weight-Bearing After Lapidus Arthrodesis
Completed NCT03846687 - Validation of Patient Reported Outcome Measures for Use in Hallux Valgus
Completed NCT04365712 - Osteotomy of the 1st Metatarsal for Hallux Valgus Using Pneumatic Oscillating Saw or Piezoelectric Scalpel N/A
Recruiting NCT02282956 - Ultrasound Guided Single Shot Block of Posterior Tibial Nerve for Postoperative Pain Relief After Hallux Valgus Surgery Phase 4
Withdrawn NCT01555216 - Continuous Tibial Nerve Block Versus Single Shot Tibial Nerve Block N/A
Completed NCT00683137 - Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery Phase 3
Terminated NCT04103814 - Effect of Topical CBD Cream for Degenerative Hallux Disorders Phase 2/Phase 3
Completed NCT03423498 - The Toe-spread-out Exercise in Patients With Hallux Valgus and Without the Deformity N/A
Not yet recruiting NCT06076655 - Hallux Valgus Treatment Developed for Children With Cerebral Palsy N/A